Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

InMed Pharmaceuticals Inc. (INM)

2.468   -0.122 (-4.71%) 12-06 09:48
Open: 2.54 Pre. Close: 2.59
High: 2.56 Low: 2.44
Volume: 11,431 Market Cap: 3(M)

Technical analysis

as of: 2022-12-06 9:19:39 AM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 4.49     One year: 5.54
Support: Support1: 2.4    Support2: 1.99
Resistance: Resistance1: 3.85    Resistance2: 4.75
Pivot: 2.84
Moving Average: MA(5): 2.65     MA(20): 2.81
MA(100): 6.66     MA(250): 16.32
MACD: MACD(12,26): -0.5     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 7.2     %D(3): 8.6
RSI: RSI(14): 39.7
52-week: High: 38.5  Low: 0.46
Average Vol(K): 3-Month: 1,537 (K)  10-Days: 149 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ INM ] has closed above bottom band by 33.6%. Bollinger Bands are 70.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.7 - 2.72 2.72 - 2.73
Low: 2.53 - 2.54 2.54 - 2.55
Close: 2.57 - 2.59 2.59 - 2.61

Company Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Headline News

Tue, 06 Dec 2022
Chloe and Halle Bailey Reveal Their Definition of Beauty - Shondaland.com

Sat, 03 Dec 2022
Brendan O'Connor sues Mediahuis over data breach - Irish Examiner

Fri, 02 Dec 2022
InMed Pharmaceuticals Inc (INM) Stock Loses -4.21% This Week; Should You Buy? - InvestorsObserver

Fri, 02 Dec 2022
The impact of COVID‐19 on the mental health workforce: A rapid review - Wiley

Tue, 22 Nov 2022
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding - StreetInsider.com

Fri, 18 Nov 2022
Is InMed Pharmaceuticals Inc (INM) Stock a Smart Value Friday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 1 (M)
% Held by Insiders 805860 (%)
% Held by Institutions 0.5 (%)
Shares Short 39 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.397e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 5.3
Return on Equity (ttm) -55.6
Qtrly Rev. Growth 1.41e+006
Gross Profit (p.s.) 0
Sales Per Share -176.62
EBITDA (p.s.) 424648
Qtrly Earnings Growth -1.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -15 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 13690
Dividend Yield 0%
Dividend Pay Date 2020-07-05
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.